Atlas Trials

A Randomized, Double-blind, Placebo-controlled Study of Delandistrogene Moxeparvovec (SRP-9001) for Duchenne Muscular Dystrophy (DMD)

Clinical trial NCT03769116 · COMPLETED

Trial details

NCT number
NCT03769116
Sponsor
Sarepta Therapeutics, Inc.
Status
COMPLETED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Muscular Dystrophy, Duchenne
Start date
2018-12-05
Primary completion
2020-12-08
Enrollment
41

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.